ESEhesan U. Sharif

Ehesan U. Sharif

*This is an algorithmically generated author record based on publicly available information.

Ehesan U. Sharif has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors

    by Corinne N. Foley, Shiwei Qu, Srinivas Reddy Paladugu, Manjunath Lamani, Rebecca Grange, Ehesan U. Sharif, Joice Thomas, Pradeep Nareddy, Guiling Zhao, Yu Chen, et al.

    High expression of the membrane-bound receptor tyrosine kinase AXL is linked to poor patient outcomes and therapeutic resistance in a variety of cancers. Selective inhibition of AXL is a promising approach to overcome mechanisms of resistance to standard of care therapies, but it is unclear if reported inhibitors have achieved an appropriate therapeutic window to effectively block AXL signaling in tumors. Herein, we report the initial design and structure-activity relationship (SAR)-driven optimization of a novel series of 7-azaindazole AXL inhibitors. These efforts identified a suitable tool compound for in vivo studies that demonstrated a significant reduction in tumor volume in combination with standard-of-care therapies. Further optimization culminated in the discovery of lead compound 68, a molecule with favorable potency, kinome selectivity, oral bioavailability, and safety. SAR insights gained from this campaign helped guide subsequent optimization efforts that ultimately led to the identification of clinical development candidate AB801.


  • Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy

    by Dillon H. Miles, Manjunath Lamani, Srinivas Reddy Paladugu, Shiwei Qu, Corinne N. Foley, Ehesan U. Sharif, Joice Thomas, Pradeep Nareddy, Joel W. Beatty, Balint Gal, et al.

    AXL receptor tyrosine kinase (AXL), a transmembrane protein highly expressed in a variety of cancers, has been implicated in the development of resistance to various forms of therapy and poor patient outcomes. Although several strategies have been postulated to limit AXL signaling and thus tumor growth, further refinement is possible. In this Drug Annotation, we report the structure-based design, SAR-driven optimization, preclinical pharmacokinetics (PK), and synthetic chemistry which enabled the discovery of AB801. AB801 is a novel, highly potent, selective, and orally bioavailable AXL inhibitor. In addition to its characterization in a variety of in vitro assays and in vivo studies, AB801 was recently dosed in healthy volunteers and is currently being evaluated clinically as a single agent in advanced solid tumors and in combination with chemotherapy for the treatment of nonsmall cell lung cancer (NSCLC).


  • Development of a Robust and Scalable Synthetic Route for a Potent and Selective Isoindolinone PI3Kγ Inhibitor

    by Artur K. Mailyan, Guillaume Mata, Dillon H. Miles, Ehesan U. Sharif, Manmohan R. Leleti, Jay P. Powers, Jenna L. Jeffrey


  • Open Access

    Abstract 1367: HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment

    by Rajesh K. Singh, Rameshwari Rayaji, Bindi Patel, Kristen Zhang, Sachie Marubayashi, Soonweng Cho, Stefan Garrido-Shaqfeh, Joseph Kulusich, Cesar Meleza, Nidhi Tibrewal, et al.

    Introduction: T cell activation is critical in the initiation and potentiation of anti-tumor immune responses. Hematopoietic Progenitor Kinase 1 (HPK1/MAP4K1) is a member of the MAP4K family whose activity has been demonstrated to restrain T cell activation through phosphorylation of SLP-76 at Serine 376 leading to TCR disassembly. Mediators generated in the tumor microenvironment (TME) such as adenosine, PGE2 and TGFβ can dampen T cell activity and present a significant barrier to cancer therapy. HPK1 inhibition may allow for enhanced T cell activation under such suppressive conditions. Herein, we describe studies to assess the effects of HPK1 inhibition on T cell activation and in alleviating suppression. We also test the ability of HPK1 inhibition in combination with adenosine receptor antagonism to further amplify T cell activation. Methods: CD8+ T cells were isolated from human blood and RNA was isolated for qPCR analysis of MAP4K1-7 expression. Cells were activated using CD3/28 stimulation and supernatants were assayed for IL-2, IFNɣ and TNFα using CBA. CRISPR knockout of HPK1 in CD8+ T cells and reference or in-house HPK1 inhibitors used to characterize HPK1 function. We used a flow cytometry-based assay to quantify activation markers CD69 and CD25, and phospho-SLP-76 in isolated CD8+ T cells and in human and mouse whole blood. Results: Using publicly available gene expression databases, we identified that HPK1 is primarily expressed in immune cells, with highest expression in T cells, B cells, and dendritic cells. In-house gene expression analyses demonstrated that HPK1 is the predominant MAP4K family member in human T cells. CRISPR knockout in primary human CD8+ T cells was used to demonstrate that HPK1 but not MAP4K3 and MAP4K4 negatively regulates T cell activation. Consistent with this, reference and in-house HPK1 kinase inhibitors reduced phosphorylation of SLP-76 in both isolated T cells and human and mouse whole blood. In human T cells, HPK1 inhibition dose-dependently increased IL-2, IFNɣ and TNFα secretion, highlighting the negative role of HPK1 in T cell activation. Using adenosine, PGE2 and TGFβ, expression of CD69 and T cell cytokine secretion is diminished. HPK1 inhibition restored T cell activation to unsuppressed levels. Consistent with these results, HPK1KO CD8+ T cells displayed significant resistance to adenosine, PGE2 and TGFβ-induced immunosuppression. Finally, upon suppression using adenosine, combining HPK1 inhibition with adenosine receptor antagonism further elevated T cell activation above individual inhibitor treatments alone. Conclusion: These data demonstrate that HPK1 plays a significant role in dampening T cell activation and provide a strong therapeutic rationale for targeting HPK1 to relieve T cell immunosuppression in the TME and amplify anti-tumor immune responses. Citation Format: Rajesh K. Singh, Rameshwari Rayaji, Bindi Patel, Kristen Zhang, Sachie Marubayashi, Soonweng Cho, Stefan Garrido-Shaqfeh, Joseph Kulusich, Cesar Meleza, Nidhi Tibrewal, Joice Thomas, Pradeep Nareddy, Ehesan Sharif, Sharon Zhao, David Green, Manmohan R. Leleti, Jay P. Powers, Daniel DiRenzo, Matthew J. Walters. HPK1 inhibition enhances T cell activation and relieves the immunosuppressive phenotype of inhibitory signals found in the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1367.


  • Design, Synthesis, and Structure–Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ)

    by Guillaume Mata, Dillon H. Miles, Samuel L. Drew, Jeremy Fournier, Kenneth V. Lawson, Artur K. Mailyan, Ehesan U. Sharif, Xuelei Yan, Joel W. Beatty, Jesus Banuelos, et al.

    Phosphoinositide-3-kinase γ (PI3Kγ) is highly expressed in immune cells and promotes the production and migration of inflammatory mediators. The inhibition of PI3Kγ has been shown to repolarize the tumor immune microenvironment to a more inflammatory phenotype, thereby controlling immune suppression in cancer. Herein, we report the structure-based optimization of an early lead series of pyrazolopyrimidine isoindolinones, which culminated in the discovery of highly potent and isoform-selective PI3Kγ inhibitors with favorable drug-like properties. X-ray cocrystal structure analysis, molecular docking studies, and detailed structure–activity relationship investigations resulted in the identification of the optimal amide and isoindolinone substituents to achieve a desirable combination of potency, selectivity, and metabolic stability. Preliminary in vitro studies indicate that inhibition of PI3Kγ with compound 56 results in a significant immune response by increasing pro-inflammatory cytokine gene expression in M1 macrophages.


  • Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors

    by Ehesan U. Sharif, Jaroslaw Kalisiak, Kenneth V. Lawson, Dillon H. Miles, Eric Newcomb, Erick A. Lindsey, Brandon R. Rosen, Laurent P. P. Debien, Ada Chen, Xiaoning Zhao, et al.

    Solid tumors are often associated with high levels of extracellular ATP. Ectonucleotidases catalyze the sequential hydrolysis of ATP to adenosine, which potently suppresses T-cell and NK-cell functions via the adenosine receptors (A2a and A2b). The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine. Thus, increased CD73 enzymatic activity in the tumor microenvironment is a potential mechanism for tumor immune evasion and has been associated with poor prognosis in the clinic. CD73 inhibition is anticipated to restore immune function by skirting this major mechanism of adenosine generation. We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design. Key binding interactions of the known inhibitor adenosine-5′-(α,β-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs. The structure–activity relationship study guided by this structure-based design led to the discovery of 4a, which exhibits excellent potency against CD73, exquisite selectivity against related ectonucleotidases, and a favorable pharmacokinetic profile.


  • Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors

    by Dillon H. Miles, Xuelei Yan, Rhiannon Thomas-Tran, Jeremy Fournier, Ehesan U. Sharif, Samuel L. Drew, Guillaume Mata, Kenneth V. Lawson, Elaine Ginn, Kent Wong, et al.

    The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3Kγ offers a promising strategy in immuno-oncology, which has led to the development of numerous potent PI3Kγ inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3Kγ inhibition, we required a potent and PI3Kγ-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3Kγ inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3Kγ-selective inhibitors for use in immunomodulation.


  • Discovery of Potent and Selective PI3Kγ Inhibitors

    by Samuel L. Drew, Rhiannon Thomas-Tran, Joel W. Beatty, Jeremy Fournier, Kenneth V. Lawson, Dillon H. Miles, Guillaume Mata, Ehesan U. Sharif, Xuelei Yan, Artur K. Mailyan, et al.

    The selective inhibition of the lipid signaling enzyme PI3Kγ constitutes an opportunity to mediate immunosuppression and inflammation within the tumor microenvironment but is difficult to achieve due to the high sequence homology across the class 1 PI3K isoforms. Here, we describe the design of a novel series of potent PI3Kγ inhibitors that attain high isoform selectivity through the divergent projection of substituents into both the ‘selectivity’ and ‘alkyl-induced’ pockets within the ATP binding site of PI3Kγ. These efforts have culminated in the discovery of 5‐[2‐amino‐3‐(1‐methyl‐1H‐pyrazol‐4‐yl)pyrazolo[1,5‐a]pyrimidin‐5‐yl]‐2‐[(1S)‐1‐cyclopropylethyl]‐7‐(trifluoromethyl)‐2,3‐dihydro‐1H‐isoindol‐1‐one (4, IC50 = 0.064 µM, THP-1 cells), which displays >700-fold selectivity for PI3Kγ over the other class I isoforms and is a promising step towards the identification of a clinical development candidate. The structure-activity relationships identified throughout this campaign demonstrate that greater γ-selectivity can be achieved by inhibitors that occupy an ‘alkyl-induced’ pocket and possess bicyclic hinge-binding motifs capable of forming more than one hydrogen bond to the hinge region of PI3Kγ.


  • Discovery of AB680: A Potent and Selective Inhibitor of CD73

    by Kenneth V. Lawson, Jaroslaw Kalisiak, Erick A. Lindsey, Eric T. Newcomb, Manmohan Reddy Leleti, Laurent Debien, Brandon R. Rosen, Dillon H. Miles, Ehesan U. Sharif, Jenna L. Jeffrey, et al.

    Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO). Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression. Extensive interrogation of structure–activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73. AB680 is further characterized by very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in phase 1 clinical trials. Initial data show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-administration in human.


  • Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2b Receptor Antagonist

    by Ehesan U. Sharif, Dillon H. Miles, Brandon R. Rosen, Jenna L. Jeffrey, Laurent P. P. Debien, Jay P. Powers, Manmohan Reddy Leleti